A detailed history of Alliancebernstein L.P. transactions in Immunovant, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 70,650 shares of IMVT stock, worth $1.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
70,650
Previous 71,450 1.12%
Holding current value
$1.94 Million
Previous $1.89 Million 3.02%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$27.51 - $27.51 $22,008 - $22,008
-800 Reduced 1.12%
70,650 $1.94 Million
Q2 2024

Aug 14, 2024

BUY
$25.1 - $31.61 $107,930 - $135,923
4,300 Added 6.4%
71,450 $1.89 Million
Q1 2024

May 14, 2024

SELL
$30.27 - $43.79 $172,841 - $250,040
-5,710 Reduced 7.84%
67,150 $2.17 Million
Q4 2023

Feb 14, 2024

SELL
$31.31 - $44.19 $50,096 - $70,704
-1,600 Reduced 2.15%
72,860 $3.07 Million
Q3 2023

Nov 14, 2023

BUY
$18.55 - $39.96 $106,848 - $230,169
5,760 Added 8.38%
74,460 $2.86 Million
Q2 2023

Aug 15, 2023

BUY
$14.2 - $23.75 $161,880 - $270,750
11,400 Added 19.9%
68,700 $1.3 Million
Q1 2023

May 15, 2023

SELL
$15.27 - $19.72 $357,318 - $461,448
-23,400 Reduced 29.0%
57,300 $888,000
Q4 2022

Feb 14, 2023

SELL
$6.59 - $17.75 $34,927 - $94,075
-5,300 Reduced 6.16%
80,700 $1.43 Million
Q3 2022

Nov 15, 2022

BUY
$3.93 - $6.37 $9,432 - $15,288
2,400 Added 2.87%
86,000 $480,000
Q2 2022

Aug 15, 2022

BUY
$3.38 - $5.65 $11,830 - $19,775
3,500 Added 4.37%
83,600 $326,000
Q1 2022

May 13, 2022

BUY
$5.06 - $8.77 $1,011 - $1,754
200 Added 0.25%
80,100 $441,000
Q4 2021

Feb 14, 2022

SELL
$7.33 - $9.32 $33,718 - $42,872
-4,600 Reduced 5.44%
79,900 $681,000
Q3 2021

Nov 10, 2021

SELL
$7.01 - $11.37 $56,080 - $90,960
-8,000 Reduced 8.65%
84,500 $734,000
Q2 2021

Jul 30, 2021

BUY
$9.4 - $16.85 $554,600 - $994,150
59,000 Added 176.12%
92,500 $978,000
Q1 2021

May 06, 2021

SELL
$13.08 - $49.6 $574,695 - $2.18 Million
-43,937 Reduced 56.74%
33,500 $537,000
Q4 2020

Feb 08, 2021

SELL
$36.36 - $52.71 $3.56 Million - $5.16 Million
-97,978 Reduced 55.85%
77,437 $3.58 Million
Q3 2020

Nov 12, 2020

BUY
$22.61 - $38.9 $1.51 Million - $2.6 Million
66,756 Added 61.44%
175,415 $6.17 Million
Q2 2020

Aug 13, 2020

BUY
$13.87 - $28.44 $742,114 - $1.52 Million
53,505 Added 97.01%
108,659 $2.65 Million
Q1 2020

May 14, 2020

BUY
$8.36 - $17.13 $461,087 - $944,788
55,154 New
55,154 $858,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.